New therapies for obesity
Research output: Contribution to journal › Review › Research › peer-review
Standard
New therapies for obesity. / Papamargaritis, Dimitris; le Roux, Carel W.; Holst, Jens J.; Davies, Melanie J.
In: Cardiovascular Research, Vol. 119, No. 18, 2023, p. 2825–2842.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - New therapies for obesity
AU - Papamargaritis, Dimitris
AU - le Roux, Carel W.
AU - Holst, Jens J.
AU - Davies, Melanie J.
PY - 2023
Y1 - 2023
N2 - Obesity is a chronic disease associated with serious complications and increased mortality. Weight loss (WL) through lifestyle changes results in modest WL long-term possibly due to compensatory biological adaptations (increased appetite and reduced energy expenditure) promoting weight gain. Bariatric surgery was until recently the only intervention that consistently resulted in >= 15% WL and maintenance. Our better understanding of the endocrine regulation of appetite has led to the development of new medications over the last decade for the treatment of obesity with main target the reduction of appetite. The efficacy of semaglutide 2.4 mg/week-the latest glucagon-like peptide-1 (GLP-1) receptor analogue-on WL for people with obesity suggests that we are entering a new era in obesity pharmacotherapy where >= 15% WL is feasible. Moreover, the WL achieved with the dual agonist tirzepatide (GLP-1/glucose-dependent insulinotropic polypeptide) for people with type 2 diabetes and most recently also obesity, indicate that combining the GLP-1 with other gut hormones may lead to additional WL compared with GLP-1 receptor analogues alone and in the future, multi-agonist molecules may offer the potential to bridge further the efficacy gap between bariatric surgery and the currently available pharmacotherapies.
AB - Obesity is a chronic disease associated with serious complications and increased mortality. Weight loss (WL) through lifestyle changes results in modest WL long-term possibly due to compensatory biological adaptations (increased appetite and reduced energy expenditure) promoting weight gain. Bariatric surgery was until recently the only intervention that consistently resulted in >= 15% WL and maintenance. Our better understanding of the endocrine regulation of appetite has led to the development of new medications over the last decade for the treatment of obesity with main target the reduction of appetite. The efficacy of semaglutide 2.4 mg/week-the latest glucagon-like peptide-1 (GLP-1) receptor analogue-on WL for people with obesity suggests that we are entering a new era in obesity pharmacotherapy where >= 15% WL is feasible. Moreover, the WL achieved with the dual agonist tirzepatide (GLP-1/glucose-dependent insulinotropic polypeptide) for people with type 2 diabetes and most recently also obesity, indicate that combining the GLP-1 with other gut hormones may lead to additional WL compared with GLP-1 receptor analogues alone and in the future, multi-agonist molecules may offer the potential to bridge further the efficacy gap between bariatric surgery and the currently available pharmacotherapies.
KW - Obesity
KW - Pharmacotherapy
KW - Bariatric surgery
KW - Semaglutide
KW - Tirzepatide
KW - Liraglutide
KW - LIFE-STYLE INTERVENTION
KW - GLP-1 RECEPTOR AGONIST
KW - LIRAGLUTIDE 3.0 MG
KW - QUALITY-OF-LIFE
KW - CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE
KW - CARDIOVASCULAR RISK-FACTORS
KW - TYPE-2 DIABETES-MELLITUS
KW - WEIGHT-LOSS MAINTENANCE
KW - SEMAGLUTIDE 2.4 MG
KW - POST-HOC ANALYSIS
U2 - 10.1093/cvr/cvac176
DO - 10.1093/cvr/cvac176
M3 - Review
C2 - 36448672
VL - 119
SP - 2825
EP - 2842
JO - Cardiovascular Research
JF - Cardiovascular Research
SN - 0008-6363
IS - 18
ER -
ID: 330888777